融资融券余额9718.08万元，较昨日上涨4.26%。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-21 | 397.40万 | 9718.08万 | 6.49% | | 2025-08-20 | 297.10万 | 9320.68万 | 6.13% | | 2025-08-19 | 572.23万 | 9023.58万 | 5.92% | | 2025-08-18 | 316.90万 | 8451.35万 | 5.48% | | 2025-08-15 | -1943.01万 | 8046.44万 | 5.23% | 证券之星消息，8月21日，威高血净（603014）融资买入1632.69万元，融资偿还1235.3万元，融资净买 入397.4万元，融资余额9718.08万元，近3个交易日已连续净买入累计1266.73万元，近20个交易日中有 13个交易日出现融资净买入。 融券方面，当日无融券交易。 小知识 融资融券：目前，个人投资者参与融资融券主要需要具备2个条件：1、从事证券交易至少6个月；2、账 户资产 ...

Core Viewpoint - Weigao Blood Purification's stock closed at 40.02 yuan, down 1.19%, with a rolling PE ratio of 35.98 times and a total market value of 16.464 billion yuan [1] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the R&D, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% [1] Financial Performance - In Q1 2025, the company reported revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% [2] - The gross profit margin for the company stands at 40.92% [2] Market Position - The average PE ratio for the medical device industry is 59.49 times, while the median is 40.19 times, placing Weigao Blood Purification at the 70th position in the industry [1][2] - The company has 59,754 shareholders as of May 19, 2025, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Industry Overview - On August 18, the medical device industry experienced a rise of 1.45% with a net outflow of main funds amounting to 820 million yuan [1] - A total of 76 constituent stocks increased in value, while 21 stocks saw a decline [1] Fund Flow Analysis - The stocks with the highest net outflow of main funds included Weigao Blood Products (18.8683 million yuan), Shengxiang Biology (16.752 million yuan), New Industry (16.470 million yuan), Dongfulong (15.4047 million yuan), and Weisi Medical (15.0001 million yuan) [1] Stock Performance - Notable stock performances included: - Furuide (60.19 yuan) with a rise of 0.01% and a net inflow of 146 million yuan, accounting for 11.88% of the main fund [1] - Lepu Medical (18.49 yuan) increased by 7.5% with a net inflow of 121 million yuan, representing 7.97% of the main fund [1] - United Imaging (129.66 yuan) saw a 1.33% increase with a net inflow of 87.19 million yuan, making up 8.77% of the main fund [1] - Sanxin Medical (11.11 yuan) rose by 0.89% with a net inflow of 44.13 million yuan, which is 8.05% of the main fund [1] - Sainuo Medical (41.48 yuan) surged by 19.99% with a net inflow of 36.44 million yuan, accounting for 1.44% of the main fund [1] - Huatai Medical (287.92 yuan) decreased by 3.19% with a net outflow of 32.11 million yuan, representing 6.49% of the main fund [1] - Sanofi Biological (21.02 yuan) increased by 0.82% with a net inflow of 30.33 million yuan, making up 9.88% of the main fund [1] - Mindray Medical (236.65 yuan) saw a slight increase of 0.62% with a net inflow of 875.74 thousand yuan, accounting for 1.49% of the main fund [1] - Aide Biological (24.22 yuan) increased by 1.32% with a net inflow of 239.15 thousand yuan, representing 6.53% of the main fund [1] - Mingde Biological (20.98 yuan) rose by 1.01% with a net inflow of 1717.08 thousand yuan, which is 14.09% of the main fund [1]

Core Viewpoint - The company, Weigao Blood Purification, has a current market capitalization of 16.271 billion yuan and a rolling PE ratio of 35.56, which is below the industry average of 55.76 [1][2] Group 1: Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including hemodialysis devices, dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for hemodialysis devices at 32.5% and for dialysis tubing at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% for its exclusive brand Weigao Tailmao [1] Group 2: Financial Performance - In the first quarter of 2025, the company reported revenue of 896 million yuan, reflecting a year-on-year increase of 6.44% [2] - The net profit for the same period was 112 million yuan, showing a year-on-year growth of 7.91%, with a gross profit margin of 40.92% [2] - The company is held by 50 institutions, with a total holding of 0.73 million shares, valued at 0.00 billion yuan [1]

天眼查商业履历信息显示，山东威高血液净化制品股份有限公司，成立于2004年，位于威海市，是一家 以从事专用设备制造业为主的企业。企业注册资本41139.4066万人民币，实缴资本37025.46万人民币。 公司法定代表人为宋修山。 通过天眼查大数据分析，山东威高血液净化制品股份有限公司共对外投资了13家企业，参与招投标项目 2050次，知识产权方面有商标信息40条，专利信息387条，此外企业还拥有行政许可59个。 来源：金融界 金融界消息 截至2025年8月13日收盘，威高血净（603014）报收于40.94元，下跌0.07%，换手率 11.84%，成交量4.51万手，成交金额1.84亿元。 资金流向方面，今日主力资金净流出1424.54万元，占比成交额7.73%。其中，超大单净流出559.06万 元、占成交额3.03%，大单净流出865.49万元、占成交额4.7%，中单净流出流入358.95万元、占成交额 1.95%，小单净流入1065.60万元、占成交额5.78%。 威高血净最新一期业绩显示，截至2025一季报，公司营业总收入8.96亿元、同比增长6.44%，归属净利 润1.12亿元，同比增长7.91%， ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Weigao Blood Purification, noting its stock price, market capitalization, and industry comparisons [1][2] - As of August 11, Weigao Blood Purification's stock closed at 40.92 yuan, with a rolling PE ratio of 36.79, marking a new low in 60 days, and a total market value of 16.834 billion yuan [1] - The company ranks 71st in the medical device industry, which has an average PE ratio of 56.56 and a median of 39.76 [1] Group 2 - The company reported a revenue of 896 million yuan for Q1 2025, reflecting a year-on-year growth of 6.44%, and a net profit of 112 million yuan, with a year-on-year increase of 7.91% [2] - The gross profit margin for the company stands at 40.92% [2] - The company holds a leading market share in the domestic blood purification sector, with a 32.5% share in blood dialysis devices and a 32.8% share in blood dialysis tubing for 2022 [1]

Core Viewpoint - Weigao Blood Purification's stock closed at 40.28 yuan, down 1.23%, with a rolling PE ratio of 36.21 times and a total market value of 16.571 billion yuan [1][2] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the research, production, and sales of blood purification medical products, including blood dialysis machines, blood dialysis tubes, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for blood dialysis machines at 32.5% and blood dialysis tubes at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% [1] Financial Performance - In Q1 2025, the company reported revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% [2] - The gross profit margin for the company stands at 40.92% [2] Market Position - The average PE ratio for the medical device industry is 55.70 times, while the median is 39.08 times, positioning Weigao Blood Purification at 70th in the industry ranking [1][2] - The company has a total of 59,754 shareholders, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder as of May 19, 2025 [1]

Core Viewpoint - The company, Weigao Blood Purification, has shown a stable performance in the medical device industry, with a notable market share in blood purification products and a competitive valuation compared to industry peers [1][2]. Company Summary - Weigao Blood Purification's stock closed at 40.78 yuan, up 2.49%, with a rolling PE ratio of 36.66, marking a new low in 58 days, and a total market capitalization of 16.777 billion yuan [1]. - The company specializes in the research, production, and sales of blood purification medical products, including hemodialysis devices, dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1]. - In 2022, Weigao held the largest market share in China for hemodialysis devices at 32.5% and for dialysis tubing at 32.8%. It ranked fifth in the peritoneal dialysis solution market with a 3.6% share [1]. Industry Summary - The average PE ratio for the medical device industry is 54.79, with a median of 37.86, positioning Weigao at the 72nd rank within the industry [1]. - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91%, with a gross margin of 40.92% [2]. - The company is one of 50 institutions holding shares in Weigao, with a total holding of 0.73 million shares valued at 0.00 billion yuan [1].

Group 1 - The core viewpoint of the articles highlights the performance and market position of Weigao Blood Purification, indicating a strong presence in the medical device industry, particularly in blood purification products [1][2] - As of August 5, the company's stock closed at 39.99 yuan, with a rolling PE ratio of 35.95 times and a total market capitalization of 16.452 billion yuan [1] - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, positioning Weigao Blood Purification at 72nd in the industry ranking [1][2] Group 2 - For the first quarter of 2025, the company reported an operating income of 896 million yuan, reflecting a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% year-on-year, with a gross profit margin of 40.92% [2] - The company holds a leading market share in the domestic blood purification sector, with a 32.5% share in blood dialysis devices and a 32.8% share in blood dialysis tubing, both ranking first in the industry [1] - In the peritoneal dialysis fluid market, the company’s exclusive brand Weigao Tailmao holds a 3.6% market share, ranking fifth in the industry [1]

证券代码：603014 证券简称：威高血净 公告编号：2025-012 山东威高血液净化制品股份有限公司 关于使用暂时闲置募集资金进行现金管理 到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上述产品共计 44,000 万元人民币已到期赎回，收回本金合计 44,000 万元人民币， 获得收益合计 61.83 万元人民币，具体情况如下： 单位：万元 ·本期赎回金额：44,000 万元。 ·赎回理财产品名称：结构性存款。 ·履行的审议程序：山东威高血液净化制品股份有限公司（以下简称"威高血 净"或"公司"）于 2025 年 5 月 27 日召开了第二届董事会第十一次会议和第二届监 事会第八次会议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议 案》，同意公司（含子公司，下同）在确保不影响募集资金项目建设和募集资金使用 的情况下，使用最高不超过人民币 74,000 万元（含本数）的暂时闲置募集资金进行 现金管理，增加公司收益，为公司及股东获取投资回报。 一、本次现金管理到期赎回 ...